Band P R, Maroun J, Pritchard K, Stewart D, Coppin C M, Wilson K, Eisenhauer E A
Cancer Treat Rep. 1986 Nov;70(11):1305-10.
The National Cancer Institute of Canada Clinical Trials Group conducted a phase II study of lonidamine, given in an escalating oral daily schedule to a maximum dose of 450 mg/m2 in patients with previously treated advanced breast cancer. Five responses were seen in 30 evaluable patients (17%). Treatment was discontinued because of toxicity in seven patients. Toxicity generally consisted of myalgia, nausea, vomiting, skin hyperesthesia, somnolence, and ototoxicity. All side effects were reversible and no hematologic toxicity was observed. The absence of myelosuppression and the suggestive lack of cross-resistance between lonidamine and standard chemotherapeutic drugs warrant further studies of lonidamine in breast cancer, particularly in combination with other agents.
加拿大国家癌症研究所临床试验组开展了一项关于氯尼达明的II期研究，对先前接受过治疗的晚期乳腺癌患者采用口服剂量递增方案给药，最大剂量为450mg/m²。30例可评估患者中有5例出现缓解（17%）。7例患者因毒性反应而停药。毒性反应一般包括肌痛、恶心、呕吐、皮肤感觉过敏、嗜睡和耳毒性。所有副作用均为可逆性，未观察到血液学毒性。氯尼达明不存在骨髓抑制作用，且与标准化疗药物之间可能不存在交叉耐药性，因此有必要对其在乳腺癌治疗中的应用做进一步研究，尤其是与其他药物联合使用时。
